Publications & Presentations

Presented at: AACR Annual Meeting 2022

On: Apr 11, 2022

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase

By: L. Roeker, A. Mato1, J. Brown, C. Coombs, N. Shah, et. al.

Presented at: ASH Annual Meeting

On: Dec 13, 2021

Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study

By: A. Mato, Y. Chen, A. Girvan, L. Hess, L. Bowman, et. al.

Presented at: ASH Annual Meeting

On: Dec 12, 2021

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

By: M. Wang, N. Shah, A. Alencar, J. Gerson, M. Patel, et. al.

Presented at: ASH Annual Meeting

On: Dec 12, 2021

Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

By: A. Mato, J. Pagel, C. Coombs, N. Shah, N. Lamanna, et. al.

Presented at: 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

On: Oct 7, 2021

Preclinical characterization of LOXO-783 (LOX-22783), a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor

By: A. Klippel, R. Wang, L. Puca, A. Faber, W. Shen, et. al.

Presented at: 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

On: Oct 7, 2021

Preclinical characterization of LOXO-435 (LOX-24350), a potent and highly isoform-selective FGFR3 inhibitor

By: J. Ballard, T. Kercher, D. Abraham, R. Brecht, N. Brooks, et. al.

Presented at: European Society of Haematology

On: Jun 11, 2021

Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Richter Transformation: Results from the Phase 1/2 BRUIN Study

By: A. Mato, N. Shah, N. Lamanna, T. Eyre, W. Jurczak, et. al.

Presented at: ASCO Annual Meeting 2021

On: Jun 4, 2021

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study

By: K. Jhaveri, E. Lim, E. Hamilton, C. Saura, T. Meniawy, et. al.

Published in: The Japanese Society of Hematology

On: May 14, 2021

Outcomes for Recurrent Mantle Cell Lymphoma post-BTK Inhibitor Therapy in Japan; an Administrative Database Study

By: S. Rai, Y. Tanizawa, Z. Cai, M. Tajimi, H. Asou, et. al.

Presented at: AACR Annual Meeting

On: Apr 10, 2021

Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor

By: S. Peng, C. Si, Y. Zhang, R. Van Horn, X. Lin, et. al.

Presented at: AACR Annual Meeting

On: Apr 10, 2021

Preclinical characterization of potent and selective next-generation RET inhibitors

By: G. Kolakowski, E. Anderson, J. Ballard, B. Brandhuber, K. Condroski, et. al.

Presented at: AACR Annual Meeting

On: Apr 10, 2021

Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor

By: B. Brandhuber, K. Ku, M. Lallena, C. Baquero, R. Choy, et. al.

Presented at: AACR Annual Meeting

On: Apr 10, 2021

Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

By: S. Bhagwat, B. Zhao, W. Shen, C. Mur2, R. Barr, et. al.

Published in: The Lancet

On: Mar 6, 2021

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

By: Anthony R Mato, MD Nirav N Shah, MD Wojciech Jurczak, MD Chan Y Cheah, MBBS John M Pagel, MD Jennifer A Woyach, MD et al.

Presented at: ASH Annual Meeting

On: Dec 7, 2020

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor In Previously Treated CLL/SLL: Results From The Phase 1/2 BRUIN Study

By: A. Mato, J. Pagel, C. Coombs, N. Shah, N. Lamanna, et. al.

Presented at: ASH Annual Meeting

On: Dec 5, 2020

LOXO-305, a Next Generation, Highly Selective, NonCovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

By: M. Wang, N. Shah, A. Alencar, J. Gerson, M. Patel, et. al.

Presented at: ASH Annual Meeting

On: Dec 5, 2020

In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice

By: E. Gomez, W. Wu, J. Stephens, M. Rosendahl, B. Brandhuber

Presented at: ASH Annual Meeting

On: Dec 9, 2019

LOXO-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations

By: E. Gomez, I. Lippincott, M. Rosendahl, S. Rothenberg, S. Andrews, B. Brandhuber

Presented at: ASH Annual Meeting

On: Dec 8, 2019

Results from the First-in-Human, Proof-of-Concept Phase 1 BRUIN Trial in Pretreated B-Cell Malignancies for LOXO-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

By: A. Mato, I. Flinn, J. Pagel, J. Brown, C. Cheah, et. al.

Presented at: Society of Hematologic Oncology Annual Meeting

On: Sep 12, 2018

LOXO-305, A Next Generation Non-Covalent BTK Inhibitor, for Overcoming Acquired Resistance to Covalent BTK Inhibitors

By: B. Brandhuber, E. Gomez, S. Smith, T. Eary, S. Spencer, et. al.